This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1-13 (Canceled)

Claim 14 (Currently amended) A method for prevention or treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of ~~an immunological oral tolerance inducing~~ composition comprising one or more active components selected from the group consisting of oxidized low density lipoprotein (Ox LDL) and malondialdehyde LDL (MDA-LDL) and a pharmaceutically acceptable carrier for oral administration, wherein said administration is in a sufficient amount to induce production of IL-10 or TGFβ and to suppress IFN-γ, thereby inhibiting at least one atherosclerosis-related symptom in said subject.

Claim 15-18 (Canceled)

Claim 19 (Previously presented) The method according to claim 14, wherein said active component is oxidized low density lipoprotein (Ox LDL).

Claim 20-25 (Canceled)

Claim 26 (Previously presented): The method according to claim 14, wherein said active component is malondialdehyde LDL (MDA-LDL).

Claim 27 (Currently amended) A method for prevention or treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of ~~an immunological oral tolerance inducing~~ composition consisting of modified low density lipoprotein and a pharmaceutically acceptable carrier for oral administration, wherein said administration is in a sufficient amount to induce production of IL-10 or TGFβ and to suppress IFN-γ, thereby inhibiting at least one atherosclerosis-related symptom in said subject.

Claim 28 (Currently amended) A method for prevention or treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of ~~an immunological oral~~

~~tolerance-inducing~~ composition comprising one or more active components selected from the group consisting of human modified low density lipoprotein and human oxidized low density lipoprotein and a pharmaceutically acceptable carrier for oral administration, wherein said administration is in a sufficient amount to induce production of IL-10 or TGFβ and to suppress IFN-γ, thereby inhibiting at least one atherosclerosis-related symptom in said subject.